Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful
Author: Vandana Singh | July 18, 2022 02:59pm
- France-based Enterome signed a strategic R&D collaboration and license agreement with Nestlé SA's (OTC:NSRGF) Health Science, targeting food allergies and inflammatory bowel disease (IBD).
- Enterome's internal pipeline is more focused on cancer, with phase 1/2 trials of two drug candidates underway in indications including recurrent glioblastoma and B-cell malignancies.
- The biotech is also working on a Crohn's disease prospect that is in phase 2 development in partnership with Takeda Pharmaceutical Co Ltd (NYSE:TAK).
- Now, Enterome has found a partner for its lead EndoMimics compound designed to create orally available drugs based on proteins secreted by gut bacteria.
- Nestlé will pay €40 million in cash and equity, clinical, and sales milestone payments for each licensed therapeutic candidate, plus royalties on net sales.
- Nestlé will co-develop EB1010 designed to treat inflammatory bowel disease by inducing high local secretion of the anti-inflammatory cytokine IL-10.
- Enterome will be responsible for leading drug discovery activities and bear related costs up to the investigational new drug (IND) application.
- EB1010 is due to enter clinical trials in 2023.
- Price Action: NSRGF shares are down 0.20% at $117.43 during the market session on the last check Monday.
Posted In: NSRGF NSRGY TAK